Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study. | Research

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.

Diabetes, obesity & metabolism

View on PubMed ↗Publisher’s paper ↗

Citation

Pampanelli, Simone; Terzoni, Stefano; Pantanetti, Paola; Di Loreto, Chiara; Mazzieri, Alessio; Cangelosi, Giovanni; Alberti, Sara; Badiali, Cristina; Grandone, Ilenia; Migliarelli, Sara; Castagna, Maria Grazia; Cerrai Ceroni, Mariaclaudia; Benenati, Nicoletta. (2026). Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70538